OnlineBusinessBureau.com
We are not the Better Business Bureau. We're better!
 
   About Us
   Our Ratings
   Look up a Company
   File a Complaint
   Complaint Resolution
     Center
   Resources
   Membership - Join Now!
   Member Login
   Testimonials
   Contact Us

1,846,405 companies
in our database.

Join our weekly
Consumer Fraud
Alert Newsletter



Our members proudly
display this seal!

News Releases

Back

BUYINS.NET: ZIOP SqueezeTrigger Price is $7.04. There is $259,091,008 That Short Sellers Still Need To Cover.

April 20, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) in real time and just received an alert that ZIOP is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 36802700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.04. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net .

From August 2009 to March 2017, an aggregate amount of 1386177067 shares of ZIOP have been shorted for a total dollar value of $9703239469. The ZIOP SqueezeTrigger price of $7.04 is the volume weighted average price that all shorts are short in shares of ZIOP. There is still approximately $259,091,008 of potential short covering in shares of ZIOP.

Buyins.net has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.buyins.net .

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) – ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts..

The SqueezeTrigger database of billions of short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor – Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new “Fair Market Making Requirements”
Naked Shorts (RegSho) – Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

Earnings – Predicts probability, price move and length of move before and after all US stock earnings reports
Seasonality – Predicts probability, price move and length of move based on exact time of year for all US stocks
Group Correlation – Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups
SqueezeTrigger – Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Valuation – Tracks all known valuation models and applies them.
GATS – Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies.
PatternScan – Automates tracking of every technical pattern and predicts next move in stocks.
Insider – Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders
Events – Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact:

Tom Ronk, CEO
BUYINS.NET
tomronk@gmail.com
800-715-9999


Credit Secrets Bible

Get Paid for
Doing Surveys





The Online Business Bureau -- 21441 Pacific Boulevard -- Suite 200 -- Sterling, VA 20166 -- 202-558-5282
News Releases |  News Articles |  Financial Calculators |  Contact Us |  Privacy Policy | Terms of Use & Legal Notice
Copyright © 2017 Online Business Bureau, L. C.. All Rights Reserved.
We are not affiliated with the Council of Better Business Bureaus, Inc.